Delivery Antisense Therapeutics

We have collected information about Delivery Antisense Therapeutics for you. Follow the links to find out details on Delivery Antisense Therapeutics.


Delivery of Antisense RNA Therapeutics

    https://antisenserna.eu/
    The Delivery of Antisense RNA ThERapeutics (DARTER) Action Members is a highly dedicated group of scientists, whose goal is (through COST networking tools) to allow RNA-targeting nucleic acid drugs to reach their full potential and become a mainstream therapeutic option. Antisense oligonucleotides (ASOs) are a new class of drugs that, through very specific targeting, could correct genetic ...

The delivery of antisense therapeutics - ScienceDirect

    https://www.sciencedirect.com/science/article/pii/S0169409X00000806
    Oct 31, 2000 · The term ‘Antisense Therapeutics’ or ‘Antisense Technology’ encompasses several types of nucleic acids that have the ability to modulate gene expression. The most common types of nucleic acids included in this term are antisense oligonucleotides (ODNs), ribozymes (RNA enzymes) and more recently, DNAzymes (DNA enzymes).Author: Saghir Akhtar, Marcus D. Hughes, Marcus D. Hughes, Alim Khan, Alim Khan, Mike Bibby, Majad Hussain, ...

Delivery of Antisense RNA Therapeutics: Turning Negative ...

    https://home.liebertpub.com/cfp/delivery-of-antisense-rna-therapeutics-turning-negative-resu/204/
    Delivery of Antisense RNA Therapeutics: Turning Negative Results into a Positive Development- Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in the most promising areas of biotechnology and regenerative medicine, biomedical research, clinical medicine and surgery, technology and engineering, law ...

Antisense & RNAi Therapeutics Market Size Industry ...

    https://www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market
    The global antisense & RNAi therapeutics market size was estimated at USD 1.09 billion in 2018 and is expected to witness a CAGR of 7.5% during the forecast period. Antisense technology provides the opportunity to manipulate the gene expression and this is being considered as an effective treatment for various diseases. This opportunity is being cashed on by the companies and are investing in ...

Advances in the delivery of RNA therapeutics: from concept ...

    https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0450-0
    Jun 27, 2017 · The rapid expansion of the available genomic data continues to greatly impact biomedical science and medicine. Fulfilling the clinical potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including short interfering RNAs and antisense oligonucleotides, are particularly promising ...Author: James C. Kaczmarek, Piotr S. Kowalski, Daniel G. Anderson

Delivering the promise of RNA therapeutics Nature Medicine

    https://www.nature.com/articles/s41591-019-0580-6
    The concept of RNA-targeting therapeutics—using antisense oligonucleotides (ASOs), aptamers, siRNAs, miRNAs and, more recently, synthetic mRNAs—to control the expression of disease-relevant ...

Current Trends in RNA Therapeutics Development

    https://www.ddw-online.com/therapeutics/p322575-current-trends-in-rna-therapeutics-development.html
    New in vivo RNA delivery technologies including LNP or PNP systems and the use of aptamer or antibody conjugation have overcome some of the challenges associated with delivery of RNA-based therapeutics, with the selection of the delivery system depending on the therapeutics properties, type of target cell and desired delivery route.

Local delivery of an antisense oligonucleotide for ...

    https://www.proqr.com/wp-content/uploads/downloads/2017/09/ProQR_QR-313_Local-delivery.pdf
    Local delivery of an antisense oligonucleotide for recessive dystrophic epidermolysis bullosa R Mendes, L van Wissen, MW de Jager, F van der Ham, V Brinks, T Ritsema, EM Haisma ProQR Therapeutics N.V. Leiden, the Netherlands Results (continued) Next delivery of different concentrations of QR-313 in …

Assisted delivery of antisense therapeutics in animal ...

    https://www.nature.com/articles/s41598-018-22316-7
    van der Bent, M.L., Paulino da Silva Filho, O., van Luijk, J. et al. Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a ...Author: M. Leontien van der Bent, Omar Paulino da Silva Filho, Omar Paulino da Silva Filho, Judith van Luijk...

Searching for Delivery Antisense Therapeutics?

You can just click the links above. The data is collected for you.

Related Delivery Info